Today Vimian Group signed an agreement to acquire Bova Holdings Limited (Bova), a leading companion animal health specialty pharmaceuticals company in the United Kingdom.

The company offers customised specialty pharmaceuticals for companion animals.

Established in 2017, Bova offers specialty pharmaceuticals covering a wide and expanding range of product classes. The company has more than 100 specialty pharmaceutical formulations, all raw materials and products are compliant with quality standards set out by regulatory authorities and the pharmaceuticals industry. Bova serves veterinary clinics and hospitals across the UK and in ten additional European markets through an online ordering system with deliveries within 24 hours.

Nick Bova, founder and CEO of Bova, will continue to lead the company as part of Nextmune and Vimian.